ARTERIAL AND VENOUS EMBOLISM DUE TO COVID-19 VACCINE (BIONTECH): CASE SERIES

Year 2022, , 79 - 81, 30.09.2022

Oya Güven , Lale Tuna , İbrahim Atakan Geçici , Zeynep Sümeyye Durgun , Ömer Işık

https://doi.org/10.33706/jemcr.1089785

Cited By: 1

Abstract

Introduction: Although the most prominent effect of Corona disease, respiratory disease it disrupts the vascular structure and causes vascular occlusion. Intravascular coagulation, has also begun to be observed in people who have been vaccinated. Therefore, clinicians had to add anti-coagulants or antiaggregants to the treatment.
Case Reports: In this article; We will try to present the patient who developed arterial and venous embolism after BioNTech vaccine. These patients without known vascular disease responded well to treatment.
Conclusion: The rate of sickness dropped after the vaccine was discovered to be the most effective strategy to protect against Covid-19. It was discovered that vaccinated patients exhibited symptoms similar to corona disease but had a moderate course.

Keywords

Covid-19, arterial embolism, venous embolism, BioNTech, vaccine

References

• Referans1 Çelik H, Saadoon AQ. COVID-19 with pulmonary embolism: Case report. Cumhuriyet Medical Journal 2020; 42(2), 213-215.
• Referans2 Makhoul K, Shukha Y, Hanna LA, Nitecki S, Leiderman M, Hayek T, et. al. A case of rapidly progressive upper limb ischemic necrosis in a patient with COVID-19. International Journal of Infectious Diseases 2021; 106, 401-404.
• Referans3 T.C. Sağlık Bakanlığı-COVID-19-Bilgilendirme Platformu. https://covid19.saglik.gov.tr/TR-66341/antisitokin-antiinflamatuar-tedaviler-koagulopati-yonetimi. Access:1.2.22
• Referans4 Wikipedia the free encyclopedia. https://tr.wikipedia.org/COVID-19 vaccination in Turkey. Access: 30.1.22
• Referans5 Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. Journal of thrombosis and haemostasis 2020; 18(4), 844-847.
• Referans6 Schultz NH, Sørvoll IH, Michelsen AE, Munthe LA, Lund-Johansen F, Ahlen MT, et. al. Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination. New England journal of medicine 2021; 384(22), 2124-2130.
• Referans7 Smadja DM, Yue QY, Chocron R, Sanchez O, Lillo-Le Louet A. Vaccination against COVID-19: Insight from arterial and venous thrombosis occurrence using data from VigiBase. European Respiratory Journal 2021.
• Referans8 Tissot N, Brunel AS, Bozon F, Rosolen B, Chirouze C, Bouiller K. Patients with history of covid-19 had more side effects after the first dose of covid-19 vaccine. Vaccine 2021; 39(36), 5087-5090.
• Referans9 Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et. al. Scientific and standardization committee communication: Clinical guidance on the diagnosis, prevention and treatment of venous thromboembolism in hospitalized patients with COVID-19. J ThrombHaemost 2020
• Referans10 Elnaem MH, MohdTaufek NH, Ab Rahman NS, MohdNazar NI, Zin CS, Nuffer W, et. al. COVID-19 Vaccination Attitudes, Perceptions, and Side Effect Experiences in Malaysia: Do Age, Gender, and Vaccine Type Matter? Vaccines 2021; 9(10), 1156.